Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Opinion & Analysis Axsome Therapeutics Inc AXSM

Healthcare Biotechnology
Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in developing and delivering therapies for central nervous system (CNS), conditions that have limited treatment options. The Company's two commercial products and development programs are Auvelity and Sunosi. Auvelity (dextromethorphan-bupropion) is an oral, N-methyl-D-aspartate (NMDA) receptor... see more

Opinion & Analysis (NDAQ:AXSM)

    'Undervalued' Biopharma Gets Breakthrough Status for Alzheimer's Agitation Drug

    Streetwise Reports July 2, 2020

    Biopharma to Accelerate Alzheimer Trial Completion

    Streetwise Reports March 26, 2020

    Two Stock-Moving Catalysts Expected in March for Biopharma

    Streetwise Reports February 26, 2020

    Biopharma's Phase 3 Trial Results in Migraine 'Robust,' 'Impressive'

    Streetwise Reports January 6, 2020

    Axsome Therapeutics Shares Open 82% Higher on Phase 3 MDD Trial Outcome

    Streetwise Reports December 17, 2019

    Axsome Therapeutics Investors Awaken to Positive Outcome in Phase 2 Narcolepsy Trial

    Streetwise Reports December 4, 2019